Sagimet Biosciences Inc.
The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.
Inclusion Criteria: 1. Must be willing and able to participate in the trial and provide written informed consent or assent 2. Aged ≥12 years on the date that written informed consent/ assent is provided 3. Moderate to severe acne vulgaris based on the following criteria at screening: 1. The EGSS at screening of 3 or 4. AND 2. Number of facial skin lesions: * 30 to 75 inflammatory lesions * 30 to 100 noninflammatory lesions 4. All participants with their partners, if any, must agree to the use of an acceptable method of highly effective contraception. Women of childb…
Oral, once daily
Oral, once daily
Arctuva estimate
Verify or correct the compensation shown for this listing.